Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alison Stopeck, MD
Stony Brook University
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the University of Arizona Cancer Center
Tucson, Arizona, United States
- the University of Arizona Cancer Center - North Campus
Tucson, Arizona, United States
- University of Colorado at Denver
Denver, Colorado, United States
- University of Miami and Clinics -Sylvester Comprehensive Cancer Center
Miami, Florida, United States
- Mt. Sinai (miami)
Miami Beach, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Louisiana State University Health Sciences Center - New Orleans
New Orleans, Louisiana, United States
- Healthpartners Cancer Research Center
Saint Louis Park, Minnesota, United States
- St. Luke'S Cancer Institute
Kansas City, Missouri, United States
- St. Vincent - Frontier Cancer Center
Billings, Montana, United States
- University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, United States
- Columba University Medical Center
New York, New York, United States
- Stony Brook University
Stony Brook, New York, United States
- Thomas Jefferson University- Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, United States
- Baptist Clinical Research Institute
Memphis, Tennessee, United States
- the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Nov 2021
- Primary completion
- 22 Mar 2023
- Completion
- 12 Apr 2023
- Last update posted
- 22 Jun 2023
- Registered enrollment
- 26
- Registry id
- NCT05159778
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.